Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases

Neurodegenerative drug discovery usually represents a protein target by its gene, canonical sequence, and one or a few structures. That representation can miss the molecular history accumulated by proteins that persist in the brain. Spontaneous chemistry, incomplete repair, altered turnover, proteolysis, phase transitions, and assembly remodeling generate states that may differ from the canonical target in exposure, function, and therapeutic accessibility. We call compositionally resolved species age-generated proteoforms and use molecularly aged protein states when the exact composition remains uncertain. This Review develops a target-state framework for Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and frontotemporal dementia, Huntington disease, and multiple sclerosis. It separates detection from age association, causality, brain exposure, proximal target engagement, and clinical evidence. Disease-specific analyses connect tau and amyloid-beta proteoforms, alpha-synuclein and lysosomal or mitochondrial assemblies, TDP-43 loss-of-function states, and persistent myelin or extracellular-matrix states to rational modalities and critical validation experiments. Repair, selective removal, stabilization, state-selective antibodies and small molecules, intrabodies, replacement, and synthesis control are evaluated together with blood–brain barrier transport, cellular and organelle access, pharmacokinetics, and pharmacodynamics. Each class of target state is mapped to the delivery constraint it imposes and the platform for which a precedent exists, and the exposure requirements that state selectivity implies are set out explicitly, including the fraction of a pool that must be engaged, the duration required to move a slowly accumulating state, and the consequences for dosing interval and pharmacodynamic biomarker choice. The aggregate-directed amyloid antibodies are analysed as the existing clinical test of the framework and of its limits. Machine learning remains central to proteoform identification, multimodal prioritization, structure modeling, and molecular design, provided that labels and prospective tests preserve target-state identity. Classical quantum chemistry can address bounded reaction and recognition problems. Quantum computing is treated as an exploratory implementation that requires matched classical baselines and explicit resources. The central requirement is not that an old protein be abnormal, but that a defined disease-relevant state can be selectively engaged while preserving the functional pool.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-18
DOI
https://doi.org/10.3390/pharmaceutics18111485
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases

Khaled S. Allemailem, Suleman Abdullah Almerdasi, Masood Alam Khan, Arif Khan et al.
Pharmaceutics
Alzheimer's disease research and treatments
article

Molecularly Aged Protein States as Targets for Drug Design and Delivery in Neurodegenerative Diseases

Khaled S. Allemailem, Suleman Abdullah Almerdasi, Masood Alam Khan, Arif Khan, Mona Alromaihi, Reem A. Alromaihi, Waad A. Aljohani, Abdulrahman Abdullah Almusallam
article en

Abstract

Neurodegenerative drug discovery usually represents a protein target by its gene, canonical sequence, and one or a few structures. That representation can miss the molecular history accumulated by proteins that persist in the brain. Spontaneous chemistry, incomplete repair, altered turnover, proteolysis, phase transitions, and assembly remodeling generate states that may differ from the canonical target in exposure, function, and therapeutic accessibility. We call compositionally resolved species age-generated proteoforms and use molecularly aged protein states when the exact composition remains uncertain. This Review develops a target-state framework for Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and frontotemporal dementia, Huntington disease, and multiple sclerosis. It separates detection from age association, causality, brain exposure, proximal target engagement, and clinical evidence. Disease-specific analyses connect tau and amyloid-beta proteoforms, alpha-synuclein and lysosomal or mitochondrial assemblies, TDP-43 loss-of-function states, and persistent myelin or extracellular-matrix states to rational modalities and critical validation experiments. Repair, selective removal, stabilization, state-selective antibodies and small molecules, intrabodies, replacement, and synthesis control are evaluated together with blood–brain barrier transport, cellular and organelle access, pharmacokinetics, and pharmacodynamics. Each class of target state is mapped to the delivery constraint it imposes and the platform for which a precedent exists, and the exposure requirements that state selectivity implies are set out explicitly, including the fraction of a pool that must be engaged, the duration required to move a slowly accumulating state, and the consequences for dosing interval and pharmacodynamic biomarker choice. The aggregate-directed amyloid antibodies are analysed as the existing clinical test of the framework and of its limits. Machine learning remains central to proteoform identification, multimodal prioritization, structure modeling, and molecular design, provided that labels and prospective tests preserve target-state identity. Classical quantum chemistry can address bounded reaction and recognition problems. Quantum computing is treated as an exploratory implementation that requires matched classical baselines and explicit resources. The central requirement is not that an old protein be abnormal, but that a defined disease-relevant state can be selectively engaged while preserving the functional pool.

PharmaceuticsVol. 18(11)
Qassim University (SA)
Qassim University
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon